Loading...
Nova Mentis Life Science Corp.
NMLSF•PNK
Healthcare
Biotechnology
$0.07
$-0.03(-27.77%)

Financial performance has remained strong, with revenue growing from -$28346.00 in Q4 2023 to $0.00 in Q3 2024. Gross profit continued to perform well, with margins at N/A in the latest quarter. Operating income reached $0.00 in Q3 2024, holding a steady N/A margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$122885.00. Net income rose to $459566.00, keeping EPS at $0.02. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan